Newer treatments you may hear about
Names in the news, what each is, and where each stood in the United States in November 2026. All of them belong with a doctor.
Best worked on with a clinician
Read this first
This guide explains names you may hear. It does not recommend any of them, and nothing here can be done through this app. Rules differ by country and change. Ask a doctor what applies to you.
Magnetic stimulation
Transcranial magnetic stimulation uses magnetic pulses on the scalp, in a clinic, over a number of visits. In the United States a device was first cleared for depression in 2008, for adults who had not been helped enough by other treatment.
Esketamine
Esketamine is a nasal spray related to ketamine. It is approved in the United States for adults whose depression has not lifted with other treatment. It is given only in a clinic, under supervision, in a program with strict rules, and it carries serious warnings. It is not approved for children.
Psilocybin and MDMA
- Both have been studied with therapy, in trials, with trained staff present.
- In one trial of psilocybin for depression that had not lifted, the highest dose lowered symptoms at three weeks. Side effects were common, and some people in every group had thoughts of harming themselves.
- As of November 2026 neither is approved as a treatment in the United States. The regulator turned down an application for MDMA with therapy in August 2024, saying the evidence did not show that it works and is safe.
- Outside a study they are illegal in most places, and using them alone is not what the trials tested.
Questions to ask a doctor
- Is this approved for what I have, and for someone my age?
- What did the studies find, and in people like me?
- What are the risks, and what would we try first?
- Who would give it, and where?
If things feel urgent
If you are thinking about these because nothing has helped and you are losing hope, tell a doctor or a clinician that, in those words. If you may not be safe, tap Get help.
Worried about safety? Get help
Where this comes from
- National Institute of Mental Health. (2024, March). Brain stimulation therapies. U.S. Department of Health and Human Services, National Institutes of Health.
- U.S. Food and Drug Administration. (2025). Spravato (esketamine) nasal spray, CIII: Prescribing information (NDA 211243, supplement 019).
- Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., ... Malievskaia, E. (2022). Single-dose psilocybin for a treatment-resistant episode of major depression. The New England Journal of Medicine, 387(18), 1637-1648.
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research. (2024, August 8). Complete response [Letter to Lykos Therapeutics regarding NDA 215455, midomafetamine capsules]. openFDA.
Reviewed by Alex Quiggle, LMSW on 2026-11-12.
This is general information. It does not replace advice from a doctor or clinician who knows you or your child.